Corient Private Wealth LLC Has $57.47 Million Stock Position in Masimo Co. (NASDAQ:MASI)

Corient Private Wealth LLC increased its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 8,847.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 347,683 shares of the medical equipment provider's stock after acquiring an additional 343,797 shares during the period. Corient Private Wealth LLC owned about 0.65% of Masimo worth $57,472,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Westfield Capital Management Co. LP lifted its holdings in Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock worth $185,869,000 after buying an additional 262,370 shares in the last quarter. National Bank of Canada FI lifted its holdings in Masimo by 195.6% during the 3rd quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider's stock worth $17,666,000 after buying an additional 87,675 shares in the last quarter. Lecap Asset Management Ltd. acquired a new position in Masimo during the 4th quarter worth $1,607,000. Nisa Investment Advisors LLC lifted its holdings in Masimo by 16,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider's stock worth $835,000 after buying an additional 5,022 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new position in Masimo during the 3rd quarter worth $478,000. 85.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Raymond James upped their price objective on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th. Stifel Nicolaus reissued a "buy" rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Wells Fargo & Company increased their price target on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler increased their price target on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $194.80.

Remove Ads

Masimo Trading Down 1.9 %

Masimo stock traded down $3.24 during mid-day trading on Thursday, hitting $169.50. 535,702 shares of the company's stock were exchanged, compared to its average volume of 622,618. The firm has a market capitalization of $9.14 billion, a P/E ratio of 116.90 and a beta of 1.04. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company's 50 day simple moving average is $174.99 and its 200-day simple moving average is $158.78.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. On average, equities analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current year.

Insiders Place Their Bets

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company's stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company's stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.